文献速递头颈部肿瘤放疗

放疗后EBV DNA残留的鼻咽癌辅助阿帕替尼治疗:一项生物标志物驱动的2期试验

Adjuvant Apatinib in Nasopharyngeal Carcinoma With Residual Epstein-Barr Virus DNA After Radiation Therapy: A Biomarker-Driven, Phase 2 Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-05-09

这项2期试验在放疗结束时血浆EBV DNA仍可检测到的鼻咽癌患者中给予阿帕替尼辅助治疗,23例可分析患者3年无病生存率为47.8%、总生存率为73.9%;治疗开始后28天血浆VEGF-A≤150 pg/mL者3年DFS和OS显著更优;最常见≥3级不良事件为鼻咽坏死(26%);作者结论认为放疗后短期使用抗血管生成药物可能增加坏死风险,该做法需避免。

要点

  • 放疗结束时血浆EBV DNA>0 copies/mL的鼻咽癌患者接受阿帕替尼500 mg每日一次,最长2年。
  • 23例可分析患者3年无病生存率47.8%,总生存率73.9%。
  • ≥3级不良事件最常见为鼻咽坏死(26%)、口腔/咽部疼痛(22%)和手足综合征(22%)。

核心结论

  • 作者结论认为,放疗后不久使用抗血管生成药物可能增加坏死风险,在转化和临床前研究揭示放疗与抗血管生成药物相互作用的机制之前,应避免这种做法。

研究设计与样本

  • 这是一项2期试验,首次在治疗抵抗组(放疗结束时血浆EBV DNA可检测)中使用靶向药物阿帕替尼(血管内皮生长因子受体2酪氨酸激酶抑制剂)。
  • 入组条件为放疗结束时(±1周)血浆EBV DNA>0 copies/mL;患者接受阿帕替尼500 mg每日一次,直至疾病进展、不可接受毒性或最长2年。
  • 主要终点为无病生存期(DFS);共入组25例,23例接受阿帕替尼的患者纳入分析。

主要发现

  • 23例可分析患者的3年DFS为47.8%,总生存率为73.9%。
  • 治疗开始后28天血浆VEGF-A≤150 pg/mL的患者3年DFS显著更优(66.7% vs 14.3%;P = .041),总生存率也显著更优(88.9% vs 42.9%;P = .033)。
  • 最常见的≥3级不良事件为鼻咽坏死(26%)、口腔/咽部疼痛(22%)和手足综合征(22%)。
  • 19例有连续EBV DNA数据,其中14例血浆EBV DNA清除(转为0),这14例中5例(36%)出现疾病复发或死亡;而未清除的5例全部出现疾病复发或死亡(3年DFS:64.3% vs 0%;P = .001)。

临床怎么用

  • 作者结论认为,放疗后不久使用抗血管生成药物可能增加坏死风险,在转化和临床前研究揭示放疗与抗血管生成药物相互作用的机制之前,应避免这种做法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We previously demonstrated that real-time monitoring of plasma Epstein-Barr virus DNA (EBV DNA) during chemoradiation therapy defined 4 distinct phenotypic clusters of nasopharyngeal carcinoma. In particular, the treatment-resistant group, defined as detectable EBV DNA at the end of radiation therapy, had the worst prognosis and is thought to have minimal residual disease. METHODS AND MATERIALS: This is the first phase 2 trial to use a targeted agent, apatinib (an inhibitor of vascular endothelial growth factor receptor 2 tyrosine kinase), in the treatment-resistant group. Eligible patients had plasma EBV DNA > 0 copies/mL at the end of radiation therapy (±1 week). Patients received apatinib (500 mg, once daily) until disease progression, unacceptable toxicity, or for a maximum of 2 years. The primary endpoint was disease-free survival (DFS). RESULTS: Twenty-five patients were enrolled and 23 patients who received apatinib were included in the analyses. Three-year DFS was 47.8% and overall survival was 73.9%. Patients with plasma vascular endothelial growth factor-A ≤150 pg/mL at 28 days after the initiation of treatment had significantly better 3-year DFS (66.7% vs 14.3%; P = .041) and overall survival (88.9% vs 42.9%; P = .033). The most common adverse event of grade ≥3 was nasopharyngeal necrosis (26%), oral/pharyngeal pain (22%), and hand-foot syndrome (22%). Nineteen patients had serial EBV DNA data. Fourteen patients had plasma EBV DNA clearance (turn to 0), and 5 (36%) of these 14 patients had disease recurrence or death, whereas all 5 patients without EBV DNA clearance had disease recurrence or death (3-year DFS: 64.3% vs 0%; P = .001). CONCLUSIONS: The use of antiangiogenic agents shortly after radiation therapy might increase the risk of necrosis. This approach needs to be avoided until translational and preclinical studies reveal the underlying mechanism of interaction between radiation therapy and antiangiogenic agents.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Liu X, Guo L, Xie FY, et al. Adjuvant Apatinib in Nasopharyngeal Carcinoma With Residual Epstein-Barr Virus DNA After Radiation Therapy: A Biomarker-Driven, Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2022. PMID: 35550406. doi:10.1016/j.ijrobp.2022.04.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。